{"id":"https://openalex.org/W4411701403","doi":"https://doi.org/10.1080/1061186x.2025.2525372","title":"Sacituzumab govitecan in HER2-negative breast cancer: redefining treatment paradigms","display_name":"Sacituzumab govitecan in HER2-negative breast cancer: redefining treatment paradigms","publication_year":2025,"publication_date":"2025-06-26","ids":{"openalex":"https://openalex.org/W4411701403","doi":"https://doi.org/10.1080/1061186x.2025.2525372","pmid":"https://pubmed.ncbi.nlm.nih.gov/40566991"},"language":"en","primary_location":{"id":"doi:10.1080/1061186x.2025.2525372","doi":"https://doi.org/10.1080/1061186x.2025.2525372","is_oa":false,"landing_page_url":"https://doi.org/10.1080/1061186x.2025.2525372","pdf_url":null,"source":{"id":"https://openalex.org/S100629371","display_name":"Journal of drug targeting","issn_l":"1026-7158","issn":["1026-7158","1029-2330","1061-186X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Drug Targeting","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082658710","display_name":"Avinash D. Khadela","orcid":"https://orcid.org/0000-0001-9914-8539","observed_orcids":["https://orcid.org/0000-0001-9914-8539"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Avinash Khadela","raw_affiliation_strings":["Department of Pharmacology, L. M. College of Pharmacy, Navrangpura","Assistant Professor, Department of Pharmacology, L. M. College of Pharmacy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology, L. M. College of Pharmacy, Navrangpura","institution_ids":[]},{"raw_affiliation_string":"Assistant Professor, Department of Pharmacology, L. M. College of Pharmacy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5117641175","display_name":"Kashvy R. Morakhia","orcid":"https://orcid.org/0009-0007-6399-3483","observed_orcids":["https://orcid.org/0009-0007-6399-3483"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kashvy R. Morakhia","raw_affiliation_strings":["Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura","Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy"],"raw_orcid":"https://orcid.org/0009-0007-6399-3483","affiliations":[{"raw_affiliation_string":"Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura","institution_ids":[]},{"raw_affiliation_string":"Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Nishra H. Shah","orcid":"https://orcid.org/0009-0008-6929-7021","observed_orcids":["https://orcid.org/0009-0008-6929-7021"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nishra H. Shah","raw_affiliation_strings":["Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura","Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy"],"raw_orcid":"https://orcid.org/0009-0008-6929-7021","affiliations":[{"raw_affiliation_string":"Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura","institution_ids":[]},{"raw_affiliation_string":"Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5117710688","display_name":"Vibha G. Kanjani","orcid":"https://orcid.org/0009-0006-4496-4479","observed_orcids":["https://orcid.org/0009-0006-4496-4479"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vibha G. Kanjani","raw_affiliation_strings":["Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura","Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy"],"raw_orcid":"https://orcid.org/0009-0006-4496-4479","affiliations":[{"raw_affiliation_string":"Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura","institution_ids":[]},{"raw_affiliation_string":"Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113261717","display_name":"Vraj B. Shah","orcid":"https://orcid.org/0009-0003-8080-5086","observed_orcids":["https://orcid.org/0009-0003-8080-5086"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vraj B. Shah","raw_affiliation_strings":["Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura","Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy"],"raw_orcid":"https://orcid.org/0009-0003-8080-5086","affiliations":[{"raw_affiliation_string":"Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura","institution_ids":[]},{"raw_affiliation_string":"Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5098928270","display_name":"Hetvi Bharadia","orcid":"https://orcid.org/0009-0005-2087-9256","observed_orcids":["https://orcid.org/0009-0005-2087-9256"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hetvi B. Bharadia","raw_affiliation_strings":["Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura","Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy"],"raw_orcid":"https://orcid.org/0009-0005-2087-9256","affiliations":[{"raw_affiliation_string":"Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura","institution_ids":[]},{"raw_affiliation_string":"Pharm D Section, Department of Pharmacology, L. M. College of Pharmacy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032161060","display_name":"Rushabh Kiran Kothari","orcid":"https://orcid.org/0000-0002-3910-5649","observed_orcids":["https://orcid.org/0000-0002-3910-5649"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rushabh Kothari","raw_affiliation_strings":["Medical Oncologist, Oncowin Cancer Centre, Naroda","Medical Oncologist, Oncowin Cancer Centre"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncologist, Oncowin Cancer Centre, Naroda","institution_ids":[]},{"raw_affiliation_string":"Medical Oncologist, Oncowin Cancer Centre","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056695286","display_name":"Manthan Merja","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Manthan Merja","raw_affiliation_strings":["Surgical Oncologist, Starlit Cancer Centre, Kothiya Hospital Campus"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Surgical Oncologist, Starlit Cancer Centre, Kothiya Hospital Campus","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5082658710"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.8139,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.65330661,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"33","issue":"10","first_page":"1743","last_page":"1756"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.6298999786376953,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.6298999786376953,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.22020000219345093,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.05220000073313713,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sacituzumab-govitecan","display_name":"sacituzumab govitecan","score":0.996999979019165},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.996999979019165},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9610000252723694},{"id":"https://openalex.org/keywords/hr-her2-breast-cancer","display_name":"hormone receptor-positive HER2-negative breast cancer","score":0.9459999799728394},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9100000262260437},{"id":"https://openalex.org/keywords/trop2","display_name":"TROP2","score":0.8389999866485596},{"id":"https://openalex.org/keywords/endocrine-resistance","display_name":"endocrine therapy resistance","score":0.8920000195503235},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.8870000243186951},{"id":"https://openalex.org/keywords/locally-advanced-breast-cancer","display_name":"locally advanced breast cancer","score":0.9879999756813049},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7039999961853027},{"id":"https://openalex.org/keywords/treatment-paradigm","display_name":"treatment paradigm","score":0.7360000014305115}],"concepts":[{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.695430338382721},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4654553532600403},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.41654956340789795},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3986208736896515},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35922980308532715},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29939961433410645}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D064726","descriptor_name":"Triple Negative Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D064726","descriptor_name":"Triple Negative Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1080/1061186x.2025.2525372","doi":"https://doi.org/10.1080/1061186x.2025.2525372","is_oa":false,"landing_page_url":"https://doi.org/10.1080/1061186x.2025.2525372","pdf_url":null,"source":{"id":"https://openalex.org/S100629371","display_name":"Journal of drug targeting","issn_l":"1026-7158","issn":["1026-7158","1029-2330","1061-186X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Drug Targeting","raw_type":"journal-article"},{"id":"pmid:40566991","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40566991","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of drug targeting","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":73,"referenced_works":["https://openalex.org/W167359183","https://openalex.org/W1991808212","https://openalex.org/W2099973570","https://openalex.org/W2127152525","https://openalex.org/W2434209561","https://openalex.org/W2548000951","https://openalex.org/W2611825467","https://openalex.org/W2616923195","https://openalex.org/W2789350096","https://openalex.org/W2807992990","https://openalex.org/W2887759341","https://openalex.org/W2927016413","https://openalex.org/W2951188632","https://openalex.org/W2978247762","https://openalex.org/W2996895767","https://openalex.org/W3006930853","https://openalex.org/W3017321429","https://openalex.org/W3037908423","https://openalex.org/W3038123442","https://openalex.org/W3084114043","https://openalex.org/W3093149563","https://openalex.org/W3109853980","https://openalex.org/W3161303985","https://openalex.org/W3166995079","https://openalex.org/W3170772776","https://openalex.org/W3176435782","https://openalex.org/W3191715814","https://openalex.org/W3202567615","https://openalex.org/W3210829765","https://openalex.org/W3217142275","https://openalex.org/W4205621591","https://openalex.org/W4281895526","https://openalex.org/W4283030645","https://openalex.org/W4283268578","https://openalex.org/W4285992810","https://openalex.org/W4291172221","https://openalex.org/W4291298122","https://openalex.org/W4292415327","https://openalex.org/W4294131778","https://openalex.org/W4295836952","https://openalex.org/W4300689840","https://openalex.org/W4302009910","https://openalex.org/W4306711477","https://openalex.org/W4306739715","https://openalex.org/W4311049979","https://openalex.org/W4311515606","https://openalex.org/W4313220059","https://openalex.org/W4313570786","https://openalex.org/W4316814847","https://openalex.org/W4319749520","https://openalex.org/W4323831004","https://openalex.org/W4324149036","https://openalex.org/W4327900078","https://openalex.org/W4367295906","https://openalex.org/W4367298925","https://openalex.org/W4380742325","https://openalex.org/W4381194465","https://openalex.org/W4386102828","https://openalex.org/W4386476335","https://openalex.org/W4387938462","https://openalex.org/W4389279942","https://openalex.org/W4390991030","https://openalex.org/W4391264099","https://openalex.org/W4396591230","https://openalex.org/W4399043069","https://openalex.org/W4399323701","https://openalex.org/W4399374789","https://openalex.org/W4399806007","https://openalex.org/W4399992245","https://openalex.org/W4401063434","https://openalex.org/W4403040094","https://openalex.org/W4403797792","https://openalex.org/W4411027965"],"related_works":["https://openalex.org/W4366822129","https://openalex.org/W2944156229","https://openalex.org/W7122682341","https://openalex.org/W4403838971","https://openalex.org/W4390232341","https://openalex.org/W4411288790","https://openalex.org/W7127181788","https://openalex.org/W3156985612","https://openalex.org/W4297680359","https://openalex.org/W3204283417"],"abstract_inverted_index":{"Human":[0],"epidermal":[1],"growth":[2],"factor":[3],"2-negative":[4],"breast":[5,19,25,28,52,71,86],"cancer":[6,20,29,53,72,87],"(HER2-BC)":[7],"is":[8,30,54,73,88,108],"characterised":[9],"by":[10,32,56],"the":[11,43,74,131,134,141,167,191],"lack":[12,35,44,75],"of":[13,36,45,58,69,76,82,133,143,169,181],"HER2":[14,46],"amplification":[15],"and":[16,21,38,80,101,140,179],"encompasses":[17],"triple-negative":[18,70],"hormone":[22,49,83],"receptor-positive":[23,50,84],"HER2-negative":[24,51,85],"cancer.":[26],"Triple-negative":[27],"distinguished":[31],"a":[33,103,109,121],"total":[34],"oestrogen":[37,59],"progesterone":[39,64],"receptors,":[40],"along":[41],"with":[42,61,172],"amplification.":[47],"While":[48],"marked":[55],"expression":[57],"receptors":[60],"or":[62],"without":[63],"receptors.":[65],"The":[66],"major":[67],"drawback":[68],"an":[77],"enforceable":[78],"biomarker,":[79],"that":[81,115],"endocrine":[89],"therapy":[90],"resistance.":[91],"Consequently,":[92],"these":[93,148],"therapeutic":[94,136,174],"failures":[95],"result":[96],"in":[97,125,138,146,155,183,190],"relapse/recurrence,":[98],"disease":[99,185],"progression,":[100],"ultimately":[102],"poor":[104],"prognosis.":[105],"Sacituzumab":[106,144,170],"govitecan":[107,145,171],"novel":[110],"3rd":[111],"generation":[112],"antibody-drug":[113],"conjugate":[114],"selectively":[116],"blocks":[117],"trophoblast":[118],"cell-surface":[119],"antigen-2,":[120],"highly":[122],"expressed":[123],"protein":[124],"HER2-BC.":[126],"This":[127],"review":[128],"elaborates":[129],"on":[130],"shortcomings":[132],"standard":[135],"regimens":[137],"HER2-BC":[139,158],"role":[142],"addressing":[147],"limitations.":[149],"Clinical":[150],"trials":[151,165],"proposing":[152],"its":[153],"application":[154],"locally":[156],"advanced":[157],"have":[159,186],"also":[160,187],"been":[161,188],"included.":[162],"Furthermore,":[163],"clinical":[164],"showcasing":[166],"combination":[168],"numerous":[173],"modalities":[175],"improving":[176],"patient":[177],"survival":[178],"quality":[180],"life":[182],"metastatic":[184],"included":[189],"text.":[192]},"counts_by_year":[{"year":2026,"cited_by_count":8},{"year":2025,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2025-10-10T00:00:00"}